WallStSmart

BlackRock Inc (BLK)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BlackRock Inc generates 24% more annual revenue ($25.64B vs $20.61B). BLK leads profitability with a 24.4% profit margin vs 17.3%. BSX appears more attractively valued with a PEG of 0.68. BLK earns a higher WallStSmart Score of 78/100 (B+).

BLK

Strong Buy

78

out of 100

Grade: B+

Growth: 8.7Profit: 7.5Value: 5.7Quality: 4.8
Piotroski: 2/9

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BLK.

BSXSignificantly Overvalued (-22.6%)

Margin of Safety

-22.6%

Fair Value

$46.16

Current Price

$53.93

$7.77 premium

UndervaluedFair: $46.16Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLK5 strengths · Avg: 8.8/10
Operating MarginProfitability
35.6%10/10

Strong operational efficiency at 35.6%

Market CapQuality
$165.75B9/10

Large-cap with strong market position

Profit MarginProfitability
24.4%9/10

Keeps 24 of every $100 in revenue as profit

Revenue GrowthGrowth
27.0%8/10

Revenue surging 27.0% year-over-year

EPS GrowthGrowth
45.9%8/10

Earnings expanding 45.9% YoY

BSX4 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$84.08B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

Areas to Watch

BLK3 concerns · Avg: 3.0/10
P/E RatioValuation
26.9x4/10

Moderate valuation

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-1.09B2/10

Negative free cash flow — burning cash

BSX0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : BLK

The strongest argument for BLK centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 24.4% and operating margin at 35.6%. Revenue growth of 27.0% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bear Case : BLK

The primary concerns for BLK are P/E Ratio, Piotroski F-Score, Free Cash Flow.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Key Dynamics to Monitor

BLK profiles as a growth stock while BSX is a mature play — different risk/reward profiles.

BLK carries more volatility with a beta of 1.46 — expect wider price swings.

BLK is growing revenue faster at 27.0% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BLK scores higher overall (78/100 vs 71/100), backed by strong 24.4% margins and 27.0% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BlackRock Inc

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock, Inc. is an American multinational investment management corporation based in New York City.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?